Tracking the Latest ncovid-19 Vaccines and Treatments

Tracking the Latest ncovid-19 Vaccines and Treatments

ncov2019cure.com Tracking the Latest ncovid-19 Vaccines and Treatments
Tracking the Latest ncovid-19 Vaccines and Treatments

R-Pharm Coronavirus: Russia approves for Covid-19 treatment

The Russian government approved R-Pharm COVID19 treatment and the vaccine will be launched by September or October. Read our blogs for all the latest updates.
As the whole world is after the solution to tackle this deadly virus in the form of COVID-19 SARS-2, Russia has also approved for Russia COVID-19 treatment and the whole responsibility has been provided to the R-pharm, one of the biggest pharmaceutical company in Russia. The top officials of the Russian government are insisting that they will make the treatment available for coronavirus through the R-pharm coronavirus treatment and the latest Russia coronavirus treatment update is that the vaccine will be launched by September or October. President Vladimir Putin has also stated that the hackers are also trying their best to steal the vital information from our researchers and has also stated that Russia need not steal any information from other parts of the world as well. Besides, he has also confirmed the treatment of coronavirus through Russia COVID-19 treatment.

Russia Coronavirus Updates:

Moreover, the Russian ministries have confirmed that a deal has been finalized with AstraZeneca pharmaceutical company to manufacture a COVID-19 vaccine in collaboration with the Oxford University, UK.

Proclaiming Themselves First Ones:

For Russia Coronavirus treatment update, the RDIF (Russia Direct Investment Fund) has confirmed that they could be the first ones to produce a vaccine and it can be called Russia’s COVID-19 treatment latest update. Though every country is investing in huge amounts, so far, nothing fruitful came from their side and Russia is the first to hit back COVID-19 with their researcher’s first blow and confirming Russia coronavirus treatment update with confidence. The RDIF in Russia is making this effort possible by financing for it.
Medicine COVID19 Treatment by Russia

Vladimir Putin’s Claim:

The Russian President, Vladimir Putin, has claimed that they have seen one of the dreadful parts of coronavirus impact here in Russia and so far has witnessed more than 750,000 COVID-19 cases. He also stated that Russia is the worst hit, is the fourth severely hit country by the coronavirus. So, they put their all researcher’s efforts compiled up and started researching a vaccine for the COVID-19 and their hard work paid off as well and they are the first ones to develop a vaccine against this deadly virus and confirmed it as a Russia COVID-19 treatment update. It is all made possible at the R-pharm pharmaceutical company. He also stated that within 3 months they will be cleared it is working or not.

RDIF Rubbishes The Statement:

The Russia Direct Investment Fund has made it all possible through financing that Russia got able to find a vaccination for treating COVID-19 with the assistance of the R-pharma pharmaceutical company. They also confirmed that Russia need not steal vital information from other countries’ vaccine developers as they already signed a contract with AstraZeneca PLC to manufacture vaccines for Oxford University, UK. Moreover, R-pharma is a part of the RDIF portfolio. They claimed that AstraZeneca is providing all vital processes along with ingredients to produce vaccines in Russia. Thus, making a big leap in Russia COVID-19 treatment. They said they are leaving nothing behind to help to form a vaccine for the Oxford University, UK. At last, Russia has consolidated that their full focus is on developing their home-grown vaccine but they are always available to assist Oxford-University, UK if they require any sort of help related to vaccine manufacturing. Moscow is fully focused on developing and is set for approval by next month to stop the Carnatic COVID-19 comprehensibly. Moreover, if everything went as planned the day is not far when the whole world will witness a curing vaccine from Russia to save the modern generation responsibly.

Sources:

Japan’s Homegrown COVID-19 Drug Hope Avigan Faces Rocky Future

Read about the results of Japan Homegrown COVID19 drug in the Philippines after the shipment of Avigan tablets. Check out our blogs for the COVID19 updates.

All set to begin with clinical trials of the Japanese drug Avigan in the Philippines! The Philippines is one of the 43 countries participating in the trial.

Japan covid 19 vaccine news is officially announced by the Philippine government after a shipment of 199, 000 tablets of Avigan sent by Japan as part of a grant-in-aid in Manila.

While the Japanese embassy doubts the effectiveness of the anti-flu drug Avigan in treating COVID-19, many experts are optimistic to get positive results in a fight against the SARS-CoV-2.

Previously, health professionals used drugs such as interferon, favipiravir, ribavirin, and lopinavir for the treatment of severe acute respiratory syndrome and the Middle East respiratory syndrome. However, the effectiveness of these drugs is under doubt, said the project researchers.

Homegrown Avigan Covid 19 Vaccine News
Source: News Break

Avigian may combat SARS-CoV-2

As per the Japan Homegrown covid 19 vaccine trials update, the Philippines will begin clinical trials on August 14 in Southeast Asia’s worst outbreak that will cover 100 patients with age ranges from 18-74 years.

Maria Rosario Vergeire (Health Undersecretary) said, “The Japan covid-19 vaccine trials for the  antiviral drug will be conducted across four hospitals in metropolitan Manila. Some initial preparations and regulatory procedures need to be undertaken before beginning with the clinical trials in the Philippines.

We are waiting for the trials to remain successful and once it is, the drug could be reasonably manufactured locally under license by its Japanese maker, said by Fujifilm Toyama Chemical, Leachon. Since the patent of Avigan’s active ingredient, favipiravir expired last year, local drug companies are on their way to produce a generic version of it.

The disease control center in Taiwan brings out the early embryonic deaths caused by the Avigan. One of the clinical studies conducted in Japan suggested avoiding the use in pregnancy as it can raise blood uric acid levels.

Glenmark Pharmaceuticals, a reputed drug agency in Mumbai already on its way to producing a version of favipiravir under the brand name FabiFlu. Glenmark produces 400 mg pill to meet the market requirement of Covid-19 treatment. This is because the Japan Homegrown COVID-19 vaccine trials require a patient to ingest 18 pills ( of 200 mg each).

In India, GRA and Dr. Reddy’s Laboratories will start selling the antiviral drug Avigan. The authorities made the announcement after the government approved the drug’s active ingredient, FavipiravIr for the treatment of patients infected with COVID-19.

The clinical trials for it are underway in the United States, Japan, China, the Middle East, and other countries. The effectiveness of Avigan has been confirmed in reducing fever and shortening recovery time in the patients specifically in the initial stages of infection with COVID-19.

We will count the regulatory process for Avigan as an important milestone. In the coming future, the company is expecting more approvals focusing to meet the growing demand of the market, said Mitch Wilson (CEO of GRA).

COVID-19 Cure, the optimism grows as researchers are about to begin clinical trials for Japan’s Homegrown virus drug. The Covid 19 vaccine latest update Japan brings great hope for the millions of affected worldwide.

Till now, no proven cure has come up for the virus, but the multipurpose drugs and the continuous efforts by the healthcare professionals have significantly contributed towards reducing the fatality rate.

Oxford Vaccine Enters Final Phase of COVID-19 Trials

As per the Oxford COVID, 19 vaccine update, the two Mumbai based institutes ave started the preliminaries of conducting the Covid-19 final vaccine trial.

As the current situation with COVID-19 develops and spreads fast, thousands of researchers and volunteers worldwide are working to search for a vaccine.

Optimism for finding the possible cure for Coronavirus has been growing since many clinical trials are in progress in order to evaluate potential treatments and their efficacy. One of the leading candidates for COVID-19 is being developed in the UK by Oxford University researchers.

The Oxford COVID 19 vaccine technology team is led by Sarah Gilbert, Prof Andrew Pollard, Prof. Teresa Lambe, Prof. Catherine Green, Prof Adrian Hill, and Dr. Sandy Doughlas. The professional team of scientists is working together in vaccine research.

About the Oxford COVID 19 vaccine results, more than 1,000 immunizations were given in the U.K during the phase I trial in healthy adult volunteers. In phase II oxford COVID 19 vaccine trial, the study expands as the age range of people participating includes a small number of older adults and children. This trial is a step to find out if the immune response to the vaccine in people of different ages.

Source: Times of India

As per the Oxford COVID, 19 vaccine update, the two Mumbai based institutes – King Edward Memorial Hospital and BYL Nair Hospital have started the preliminaries of conducting the Oxford University-AstraZeneca Covid-19 vaccine trial.

Must Read: Oxford COVID-19 Vaccine’s Human Clinical Trials

The Serum institute in India has partnered with Oxford-AstraZeneca and is already in the process of manufacturing 2-3 million doses by August end of 2020. There will be a total of 17 institutions in India to participate in the trial to be conducted by the Serum Institute of India, Pune.

With the approval from the government of India, it is going to conduct final-phase human trials from August 2020.  The purpose of Phase II/III is to check if a vaccine made from the weakened virus that causes the common cold in Chimps can protect from COVID.

The Covid-19 vaccine by Oxford is called AZD122 and will be manufactured and distributed in India as the Covishield vaccine which is going to cost less than 1000 INR per dose. The vaccine candidate was one of the first candidates to have begun the clinical trial stage that is currently undergoing phase 3 of the trials somewhere in Brazil.

By the end of 2020, it has also been expected to have at least 50 million Covishield doses ready, more than half of which will be supplied to the government of India with the rest being provided to the other countries, more specifically to the less developed nations.

John Bell (Professor of medicine at the University of Oxford) said “The UK is in search of a place in the world to prove leadership in the vaccine space. John is working with the UK government on its vaccine program.

Who can participate in the Oxford COVID 19 vaccine trial?  The sample size is expected to be 16000 people, out of which 400 for immune response study and 1200 to gauge safety. People from the age group 18 to 99 years participate. There is no restriction for gender as both males and females are permitted to take part in the trial.

Oxford COVID 19 vaccine results induce strong antibody and T-cell immune responses for up to 56 days after administering it. As per the report, T-cells are required for maintaining protection against the virus for years.

Good immune response has been observed in almost everybody in people aged 18 to 55 said by Dr. Adrian Hill, who is the director of the Jenner Institute at Oxford University and he added that the experimental Covid-19 produced dual response along with producing neutralizing antibodies required to block infection.

Whom to contact?

For the King Edward Memorial Hospital, call at 022-24133767, 24174420.

For the BYL Nair Hospital, contact at (022-23027644, 45)

Gilead’s Remdesivir: Australia approves for COVID 19 Treatment

Australian authority has permitted to use remdesivir for the patient critically suffering from COVID-19 and this is Australia’s coronavirus treatment update

Gilead Sciences First Treatment Option:

The deadly coronavirus which is supposed to be originated in China has engulfed the whole world in its dreadful journey so far and the pace does not seem to slow down. So, the whole world nations are putting their efforts, in finding a solution to stop this COVID-19. Like the whole world, Australia is also making a valiant effort to stop this deadly virus from piling up the casualties. The Australian government has granted permission to the Gilead’s pharmaceutical company for finding Australia COVID-19 treatment. Gilead has been gifted with the first treatment option for coronavirus treatment in Australia. 

Latest Updates:

The latest updates are suggesting that the Australian authority has permitted to use remdesivir for the patient critically suffering from COVID-19 and this is Australia’s coronavirus treatment latest update. It is showing positive symptoms as this medicine is shortening hospital stay and the patients are recovering fast and effectively. 

Remdesivir Vaccine

The TGA has also stated that Remdesivir is a perfect treatment option for seriously infected patients and it has been considered COVID-19 treatment in Australia. Besides they have also confirmed, it has massively reduced the strain from Australia’s healthcare systems because on using it, patients are recovering fast and thus are leaving hospitals early as well. Thus, making it easy for the Australian health ministry. They have also stated that it is available only for the people who are severely infected with COVID-19 and is not freely available for everyone to use. But it is assisting positively Australia coronavirus treatment. At present, it is highly recommended for the patients requiring ventilators to breathe. All in all, it is not commonly used.  

Read: How MMR Vaccine Can Prevention From Worst Symptoms of COVID 19

Proved A Milestone:

Remdesivir usage has been proved beneficial and it won’t be incorrect at all to be called a milestone because it has controlled Australia’s struggle significantly. Though it is not made available freely for everyone still it has managed successfully coronavirus treatment in Australia. While using it for severe cases, it has shown progressive indications that made the Australian Healthcare system happy and cheerful. 

Following the track, the same way from Australia, the European Union, Japan, and Singapore also made their positive enhancement to authorize the use of remdesivir for treating COVID-19. Earlier International regulatory cooperation has made it possible as both the European Medicine Agency and Singapore Health Sciences Authority shared their review reports with TGA Australia. They are also optimistic about the usage of this for treating coronavirus. The TGA has worked day and night in collaboration with Gilead Sciences to confirm the efficacy of the medicine. 

Following Threads:

Gilead Sciences First Treatment Option:

The deadly coronavirus which is supposed to be originated in China has engulfed the whole world in its dreadful journey so far and the pace does not seem to slow down. So, the whole world nations are putting their efforts, in finding a solution to stop this COVID-19. Like the whole world, Australia is also making a valiant effort to stop this deadly virus from piling up the casualties. The Australian government has granted permission to the Gilead’s pharmaceutical company for finding Australia COVID-19 treatment. Gilead has been gifted with the first treatment option for coronavirus treatment in Australia. 

Latest Updates:

The latest updates are suggesting that the Australian authority has permitted to use remdesivir for the patient critically suffering from COVID-19 and this is Australia’s coronavirus treatment latest update. It is showing positive symptoms as this medicine is shortening hospital stay and the patients are recovering fast and effectively. 

The TGA has also stated that Remdesivir is a perfect treatment option for seriously infected patients and it has been considered COVID-19 treatment in Australia. Besides they have also confirmed, it has massively reduced the strain from Australia’s healthcare systems because on using it, patients are recovering fast and thus are leaving hospitals early as well. Thus, making it easy for the Australian health ministry. They have also stated that it is available only for the people who are severely infected with COVID-19 and is not freely available for everyone to use. But it is assisting positively Australia coronavirus treatment. At present, it is highly recommended for the patients requiring ventilators to breathe. All in all, it is not commonly used.  

Proved A Milestone:

Remdesivir usage has been proved beneficial and it won’t be incorrect at all to be called a milestone because it has controlled Australia’s struggle significantly. Though it is not made available freely for everyone still it has managed successfully coronavirus treatment in Australia. While using it for severe cases, it has shown progressive indications that made the Australian Healthcare system happy and cheerful. 

Following the track, the same way from Australia, the European Union, Japan, and Singapore also made their positive enhancement to authorize the use of remdesivir for treating COVID-19. Earlier International regulatory cooperation has made it possible as both the European Medicine Agency and Singapore Health Sciences Authority shared their review reports with TGA Australia. They are also optimistic about the usage of this for treating coronavirus. The TGA has worked day and night in collaboration with Gilead Sciences to confirm the efficacy of the medicine. 

Following Threads:

On the positive note, many countries are opting for remdesivir treatment to tackle COVID-19 in their countries and without any doubt have become their A-one choice after the significant outcome in Australia. It has made Australia COVID-19 treatment way easier and accessible because this intravenously administered medicine has shown positive outcomes during the clinical trials as well and made the treatment fast and effective.  So, continue from here, the US and European Commission have also shown their positive assistance to use this for emergency use. So, the same way trend is following this therapy in Japan, India, Singapore, and the UAE. 

MMR Vaccine: Prevention From Worst Symptoms of COVID 19

MMR Vaccine can be effective against the worst symptoms of COVID 19. It can prevent lung infections as well as inflammation. Read more about MMR Vaccine.

An Effective Remedy:

As all of you know it very well that MMR stands for measles, mumps, and rubella and this MMR vaccine can be an effective remedy to treat coronavirus. Everyone knows it very well how deadly this COVID-19 impact was over the whole world and it almost shattered everything into pieces all around the world. You would be astonished to know that the existing vaccines like the MMR vaccine for coronavirus will be equally effective against this deadly pandemic. Moreover, there are numbers of evidence that shows the existing vaccinations, like the MMR vaccine, COVID-19 protection, are very beneficial even though they are not specifically made for it. 

MMR Vaccine for Coronavirus

A Protective Layer:

The doctors all over the world are testing these existing vaccinations like MMR vaccine against COVID-19 and BCG (treats TB) if they can be proved effective against this COVID-19. The scientific studies have revealed that these vaccinations can reduce the symptoms related to the world-known pandemic. Besides, MMR shot for COVID can induce MDSCs in the patient’s body that can reduce the lung infection as well as inflammation massively and can hold up other forms of severe diseases away as well. 

Besides, if a person is MMR vaccine COVID-19 vaccinated and is found positive with COVID-19 then he/she will only show mild symptoms of COVID-19 because they are very well-protected with MMR vaccine against COVID-19 and this could be your best MMR shot ever for COVID treatment. Moreover, with MMR vaccine COVID-19 protection, you are less prone to the deadly pandemic as compared to people who do not have MMR vaccination protection with them. 

Keep Children & Old One’s Safe/Secure:

The little children can also benefit from the help of this MMR vaccine for coronavirus as their body is already having a protective layer to fight against this COVID-19. Though age is a factor as well in fighting with this deadly pandemic, so if you are protected with MMR vaccine COVID-19, you are surely going to win this fight. The MMR vaccine for coronavirus provides antibodies against measles, mumps, rubella, and COVID-19. It can provide you tremendous benefits in fighting this pandemic to stay out of your body and keep the MDSCs level in your body intact and thus this MMR vaccine COVID-19 vaccination provides durability for a longer period and keep the COVID symptoms away from you. So, you are completely safe and secure with MMR short for COVID.

Moreover, the recovery rate from the COVID-19 is more because of the MMR vaccine COVID-19, that is probably the main reason that the children are also more secured with this because they are already having a protection layer in the form of MMR vaccine COVID-19 protection. So, the severity of the coronavirus can be controlled massively if we keep our children as well as old ones vaccinated with MMR vaccine COVID-19 protection. 

Less Death Rate:

Besides, if you observe minutely you will find that people who are having an MMR vaccine used massively in their day to day life, the death toll will be way less as compared to the area with more deaths because of coronavirus. Besides, an MMR vaccine COVID-19 is a protection layer you can go out with your near and dear ones safe and secure as long as you are having an MMR shot for COVID at your side.

India’s 2nd COVID 19 Vaccine for Clinical Trials

ZyCoV-D by Zydus in India is ready for the second trial COVID 19 Vaccine. The vaccine has helped to build good immune phenomena in the Animals.

The Covid-19 has brought the whole world to a standstill. Now, every country across the globe including India are putting their whole heart in to find a suitable vaccine to handle this pandemic grippingly in a solid way. As the whole world is trying, India is also doing his bit as many pharmaceutical companies are putting their valiant part in finding the proper vaccination. One such pharmaceutical giant is, Zydus Cadila who with the approval from the DCGI (Drug Controller General Of India) have manufactured a vaccination by the name, ZyCoV-D and is ready for a 2nd vaccine trial in India.

Coronavirus Vaccine Update India

They with this approval from the DCGI for India’s 2nd COVID 19 Vaccine trial to be conducted on people to find the perfect antidote to handle this deadly COVID chain. ZyCoV-D, is 2nd vaccine trials India is doing and it is seeming that it could be a successful affair this time. This is India’s second vaccine that came in the form of ZyCoV-D, developed by Zydus, in Ahmedabad, at its Vaccine technology center. Through the animal studies, it is revealed that this vaccine creates strong immune phenomena in the animal bodies. It can be called an Indian COVID latest vaccine update.

Now soon, Zydus is about to start their human trial and it could be conducted at the different sites in the country on several volunteers in the first two phases. Zydus Cadila chairman committee is confirming that within three months the trials can be completed and with the emergence of ZyCoV-D, the coronavirus vaccine update India will be strengthened. They also confirmed that after these two phases, if required, with DCGI’s approval, the company can go for the third phase as well and the people of India can know about the Indian COVID vaccine update more specifically. Moreover, they also emphasized only then the vaccine can be available in the market otherwise it can take time more time. So, coronavirus 2nd vaccine trials India is on the verge of getting into the market professionally and hopefully with positive results related to India 2nd COVID 19 Vaccine trial.

Zydus Cadila’s Chairman, Mr. Pankaj Patel, is very confident by the results this vaccine showed on the animals like mice, rats, and rabbits. So, he is quite optimistic about the coronavirus vaccine update in India. Moreover, this vaccine also enhanced tremendous immune response in the animal bodies and the vaccine showed a great efficacy in neutralizing the wild type viruses present in the animal bodies. So, this way, he is confident that it will be a successful campaign when it will be tried upon the human volunteers and thus it can make India’s 2nd COVID vaccine trial a great success story for the world to know.

Moreover, Zydus Cadila, Chairman, Mr. Pankaj Patel is also insisting that the Vaccine Technology Center, Ahmedabad, India provides massive accessibility with the minimum amount of bio-safety requirements. Besides, Zydus also revealed that the gene of interest making it very safe for human beings.

So, the Indian COVID vaccine update has confirmed ZyCoV-D, an effective antidote in treating the COVID pandemic with certain contradictions still hovering around. Moreover, on top of everything, 2nd vaccine trials India can be carried to the remotest of remotest location quite easily because of its improved stability and lower cold chain characteristics. If this vaccination yields positive results, the Vaccine Technology platform can be used for the modification of the vaccine and if it shows clear protection.

The Chairman committee further added that they are not going to export anytime soon and all they want to do to make India 2nd COVID 19 Vaccine trial a great success. They confirmed firstly that the demands within the country will be justified first, only then can think of something else. Moreover, they put more emphasis on Indian COVID vaccine update and on giving technology to other countries, so that they could also manufacture the vaccine accordingly.

So, India’s 2nd COVID vaccine trial can prove to be a great success story for the whole of the world and thus coronavirus vaccine update India can be made intact. One can easily analyze Indian COVID vaccine update through this that they are also manufacturing another vaccine, named Covaxin for treating COVID-19. Bharat Biotech, the manufacturer, has received approval from the DCGI to give it a go and soon will carry trials on humans in two phases. It is made relevant through ICMR, Indian Council for Medical Research, and soon it will be a great reality.

First Plasma Bank in India For COVID 19 Patients

The first plasma bank In India launched for COVID 19 patients. There are some conditions to donate blood plasma. To know more, visit our blog.

Endless Efforts:

All over the world, it is estimated that numbers of attempts have been made and still are making as well to find the solution to heal this SARS-CoV-2. The doctors, scientists, are also coming with conclusions but so far nothing fruitful could be gained in properly treating this deadly COVID-19. So, like other countries, India is also putting endless efforts in treating this deadly pandemic and it came in the form of first plasma bank in India.

COVID-19 First Plasma Bank

What Is Blood Plasma?

Moreover, blood plasma is one of the oldest therapy in which the doctors use blood plasma of people who have recovered from this life-threatening disease. So, to control this disease the first plasma bank for corona has been opened in New Delhi, India. People rarely know what is called plasma, so for their information, it is a portion of blood without RBC, WBC, and platelet count. So, COVID-19 first plasma bank is available here in New Delhi, India to sort out the concerns of coronavirus patients. Moreover, it can also be called a plasma donation for COVID-19 in India, as it has improved accessibility related to blood plasma in treating the deadly novel coronavirus patients. So, far blood plasma proved a successful effort against this, and COVID-19 first plasma bank is the availability center for blood plasma.

It is good that the first plasma Bank in India has been established and making everything easy for the people to acquire blood plasma as early as possible here but at the same time, it is also the duty of the people who have recovered from this deadly blow, should come forward to donate their blood in the first plasma bank for corona. So, that needs of the patients and their near and dear ones could be fulfilled easily.

How It Is Effective:

Now, how blood plasma is effective in curing the COVID-19 is also a big question in people’s minds. So, for them, people who have recovered from this deadly coronavirus usually develop the antibodies in their blood called convalescent plasma and this plasma then can be inserted into the bodies of the corona patients to boost up their immune system and this therapy is called convalescent plasma therapy. So regarding this, the whole credit should go to CM of New Delhi, Mr. Arvind Kejriwal, who has made this all possible and let New Delhi became the first state in India to come up with COVID-19 first plasma bank.


According to COVID-19 first plasma bank officials, it does not take more than an hour for a plasma donor to donate blood plasma at the plasma bank. After the basic tests of the donor and all the proceedings, the donor is given an appreciation certificate for his valiant effort.

Conditions, The Donors Should Follow:

However, it is not as if anyone can come and donate plasma straightway, the plasma donation for COVID-19 in India has their terms and conditions if you want to donate your blood plasma and conditions should be fulfilled otherwise you are not liable to do that. 

Besides, there are some conditions as well that donors should keep in mind while coming for donations. So, he/she must be at least 14-day old by recovering from the disease. Moreover, the donor should weigh more than 50 kg and the age should be in from 18-60 group maximum. So, if the donors fulfill all these conditions, only then they can donate their plasma at the first plasma bank in India.

Following Initiative:

Seeing plasma donation for COVID-19 in India positive moves, other states are also going for this blood plasma initiative. So, COVID-19 first plasma bank has made a great leap forward in eliminating the deadly novel corona clouds with their first plasma bank for corona and it is yielding fruitful results as well.

Erythropoietin: Using EPO For COVID 19 Patients

Erythropoietin is usually used for anemia but has proved beneficial for treating the COVID 19 Patients as well. To know more, read the blog.

All over the world, the doctors are trying their best in treating the COVID-19 with the existing medications and vaccinations. They are using many medications and one of such type is EPO for COVID-19. It is giving fruitful results so far in treating coronavirus. EPO stands for Erythropoietin and it is mainly used for anaemia but this medicine is proving beneficial in treating the coronavirus patients as well. The doping agent in it is effective against COVID-19.

red-blood-cell-4302093_1920Blog10

Latest Analysis:

The latest studies reveal that EPO mitigates several diseases not only anaemia. This medicine has proved beneficial in treating the brain or neurological diseases, so it can minimize the effect of novel coronavirus when it attacks the brain. So, EPO to treat COVID-19 is the best option to go with. All in all, erythropoietin for COVID-19 patients is proving a boon and the experts are doing their researches to know how EPO is treating COVID-19 patients effectively and successfully too.

Yielded Fruitful Results:

The EPO coronavirus treatment has shown progressive development when it is used on COVID-19 patients and the results were spectacular as patients recovered way faster from the deadly pandemic. Erythropoietin for COVID-19 patients improves blood values and the patient significant signs of improvement within seven days. Moreover, erythropoietin drug coronavirus is equally effective in the higher altitude regions because people here use more EPOs, so they have more RBCs and that is why they are more adaptable to deficiency of oxygen as compared to the people living in the low-lying areas.

Moreover, the EPO coronavirus treatment has shown tremendous improvement in the recovery of the patients as well as in their immune systems. If you observe, you will find that the kidney or dialysis patient have not got any signs of coronavirus because in the dialysis treatment they receive erythropoietin on almost daily basis. This is the main reason that they are not even affected with even mild illnesses. EPO to treat COVID-19 is a stimulant that many athletes use it and affects your blood cells and many other tissues positively. Moreover, this erythropoietin for COVID-19 patients covers the oxygen deficiency massively and progresses it forward to the brain and muscles effectively and that is why this EPO for COVID-19 is delivering positive results and showing signs of impressive improvement from the day the medical scheduling starts with EPO coronavirus treatment.

An Erythropoietin Drug Coronavirus Plus Points:

All over the world renowned doctors have studied a lot about the erythropoietin drug coronavirus a lot and came to the conclusion that it is giving positive results in enhancing the overall health of coronavirus patients. When it is experimented on animals, it showed positive results and it was acting on the brain stem and spinal cord that control breathing process in our system simultaneously with great effect. So, it is taking care of the breathing system in an affirmative way as COVID-19 straightway starts damaging your lungs and you find difficulty in breathing. So, you can see how effective this erythropoietin drug coronavirus is! Thus, this it offers excellent immunity in the COVID-19 patients. Moreover, this erythropoietin drug coronavirus control the normal things like headaches, dizziness, and anything related to seizures also.

So, at last, though the doctors all over the world are trying this EPO coronavirus treatment on patients, but still they are waiting to get convinced with authority though it is showing vital signs in improving the health of coronavirus patients. So, they are assuming and trying this EPO to treat COVID-19 patients but still a solid authority is yet to reveal that it is effective in the reals sense.

CureVac Started Work For Developing a COVID-19 Vaccine

CureVac AG, the first pharma company in the world using mRNA for medical purposes, is working to develop mRNA-based drugs to cure COVID 19 patients.

Beginning from the first case in China (December 2019), SARS-CoV-2 is severely affecting many countries around the world. In response to the global pandemic, researchers worldwide are using different approaches to develop a coronavirus vaccine at the earliest.

CureVac COVID19 Vaccine

To protect COVID affected patients, CureVac AG is working on the development of mRNA-based drugs for vaccines and therapeutics.

CureVac is a reputed biopharmaceutical company with headquarters in Tubingen, Germany. Founded in 2000, CureVac is the first pharma company in the world that has successfully harnessed mRNA for medical purposes. The company is proud to be part of the international helping hands towards protecting masses from the novel coronavirus. The recent success of the company relates to the Rabies program that aims to fully protect humans with two doses of only one microgram (I millionth of a gram).

The company aims to provide a cost-effective and prophylactic vaccine using unique technology. At present, their team is working on mRNA technology to bring a rapid response to prevent spreading the virus. Since 2007, the company is engaged in the prophylactic vaccine and can produce mRNA vaccines on a colossal scale.

After the Paul Ehrlich Institute, CureVac is the second German company which has begun the trial phase for the vaccine against COVID-19.

To bring practical results and to speed up the development, production, and clinical process, CureVac is in contact with various health organizations such as CEPI (Coalition for Epidemic Preparedness Innovations) and BMGF (Bill and Melinda Gates Foundation.

About mRNA Technology

A natural messenger substance, the vaccine will be a trial to activate the human body against its defence mechanism. With the mRNA technology, it is expected that the human body will recognize the protein of the coronavirus and in response will activate its immune cells to produce antibodies and T-cells against it.

Mariola Fotin-Mleczek (Chief Technology Officer of CureVac) said, “With our unique RNA technology, we prepare the human body how to fight against the virus. Our expertise and disease understanding makes us able to come up with a solution for outbreak solutions like COVID-19.

As per the recent information on the Curevac COVID trial, the company has started human trials after the idea approved by regulators. The first trial by the German biotech firm will involve 168 volunteers, of whom 144 will be given the experimental vaccine.

Many countries are contributing to bringing the coronavirus vaccine. However, projections for how long it will take to develop a vaccine vary widely. Based on the experience and knowledge, researchers need at least a year to come up with an effective solution.

Once researchers successfully create a potential vaccine then brings into the notice of the Food and Drug Administration (FDA) to check its effectiveness.

The next phase is to complete Phase I, Phase II, and Phase III clinical trials to analyze the safety and effectiveness of the drug thoroughly.

The company is expected to begin the next clinical study with several thousand participants in autumn 2020. Even if CureVac remains successful in achieving favourable results, it depends on the regulatory authorities about the availability of the vaccine on the market.

Oxford COVID-19 Vaccine’s Human Clinical Trials Started in Brazil

Brazil is the first country has signed an agreement with Oxford University for an experimental COVID 19 vaccine clinical trails.

The latest news on COVID brings that recently Brazil has signed an agreement to experimental product vaccine against COVID-19. A deal with Oxford University and a reputed pharmaceutical company, AstraZeneca has been hired to develop a vaccine that is undergoing clinical tests.

Oxford COVID 19 Vaccine Status

With the ongoing search for COVID-19, Oxford University is leading the world to bring an effective vaccine against the virus.

As per Kate Bingham (Chair of the UK Vaccine group), it is highly expected to bring a vaccine this year, from any of the candidates. The first developed Oxford COVID 19 vaccines will probably help to relieve the symptoms instead of giving full protection to the disease.

With the 283, 757 confirmed COVID cases in the UK; the country has the hope to find something protective against the virus before winter ends.  We are putting the best efforts to improve on those timelines but not sure how much sooner will be vaccine be ready to implement, said by Sarah Gilbert (Science and technology committee, Oxford University).

With the number of COVID cases increasing in Brazil and South Africa, the vaccine trial will be soon held there. AstraZeneca, the British Pharma company, has partnered with Oxford University to develop a vaccine with two billion doses in September. Meanwhile, the US is ready with two million vaccine doses to check out for effectiveness.

To maximize the production capacity of the vaccine, AstraZeneca has signed an agreement with the Serum Institute of India and CEPI (Coalition for Epidemic Preparedness Innovations). The partnership with the world’s largest vaccine manufacturers has a significant role in helping the low-and middle-income countries.

Oxford University started initial vaccine trials in April with hundreds of volunteers which is now have expanded to 10,000 contributors. Brazil is the first country outside Britain where Oxford COVID 19 Vaccines trails were started in June.

The company is proud to collaborate with the Oxford University to speed up the development and globalization of this potential new vaccine against COVID-19, said by Mene Pangalos, Executive Vice President, AstraZeneca.

In a press conference, it has been announced by the Brazilian health ministry that the country is going to invest $127 million to get material for producing 302 million doses till December. Considering the whole deal is for 100 million vaccines that will be provided by a local vaccine maker Fiocruz.

As per Soumya Swaminathan (WHO Chief Scientist), the experimental vaccine by AstraZeneca is expected to develop the world’s leading and most advanced candidate against COVID-19.

The study focuses on evaluating the way to protect people of all ages from COVID-19 with the new vaccine called ChAd0X1 nCoV-19. Also, it will provide crucial information on the safety aspects of the vaccine by expecting an excellent immune response against the virus.

Spike glycoprotein has an essential role in the infection pathway of the SARS-CoV-2 virus, which makes use of this protein to blind to ACE2 receptors on human cells. The motive of vaccinating with ChAdOx1 nCoV-19 is to make the human body develop an immune system to the spike protein that restricts the virus to human cells, thereby prevent infection.